ADAMANT

ANTIBODY DERIVATIVES AS MOLECULAR AGENTS FOR NEOPLASTIC TARGETING

Coordinatore	ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI    more  Organization address address: Via Giuseppe La Masa 19 city: MILANO postcode: 20156 contact info Titolo: Dr. Nome: Maria Rosa Cognome: Bani Email: send email Telefono: 390239000000 Fax: 390239000000
Nazionalità Coordinatore	Italy [IT]
Sito del progetto	http://www.adamant-fp7.eu
Totale costo	3˙918˙400 €
EC contributo	3˙000˙000 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2007-A
Funding Scheme	CP-FP
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-04-01   -   2011-03-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI  Organization address address: Via Giuseppe La Masa 19 city: MILANO postcode: 20156 contact info Titolo: Dr. Nome: Maria Rosa Cognome: Bani Email: send email Telefono: 390239000000 Fax: 390239000000	IT (MILANO)	coordinator	0.00
2	EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZURICH  Organization address address: Raemistrasse 101 city: ZUERICH postcode: 8092 contact info Titolo: Prof. Nome: Dario Cognome: Neri Email: send email Telefono: -6337404 Fax: -6331361	CH (ZUERICH)	participant	0.00
3	FONDAZIONE SENDO  Organization address address: Corso Venezia 18 city: MILANO postcode: 20124 contact info Titolo: Dr. Nome: Silvia Cognome: Marsoni Email: send email Telefono: -7642004 Fax: -76017447	IT (MILANO)	participant	0.00
4	FRIEDRICH-SCHILLER-UNIVERSITAT JENA  Organization address address: FURSTENGRABEN 1 city: JENA postcode: 7743 contact info Titolo: Dr. Nome: Alexander Cognome: Berndt Email: send email Telefono: -5149 Fax: -4636	DE (JENA)	participant	0.00
5	KEMOTECH SRL  Organization address address: Via Roma city: CAGLIARI postcode: 9123 contact info Titolo: Dr. Nome: Matteo Cognome: Zanda Email: send email Telefono: -23993047 Fax: -23993043	IT (CAGLIARI)	participant	0.00
6	PHILOCHEM AG  Organization address address: WOLFGANG PAULI STRASSE 10 city: ZURICH postcode: 8093 contact info Titolo: Dr. Nome: Eveline Cognome: Trachsel Email: send email Telefono: -6337867 Fax: -6331484	CH (ZURICH)	participant	0.00
7	UNIVERSITE DE LIEGE  Organization address city: LIEGE postcode: 4000 contact info Titolo: Dr. Nome: Isabelle Cognome: Halleux Email: send email Telefono: -43665396 Fax: -43665526	BE (LIEGE)	participant	0.00
8	UNIVERSITY COLLEGE LONDON  Organization address address: GOWER STREET city: LONDON postcode: WC1E 6BT contact info Titolo: Dr. Nome: Rosamund Barbara Cognome: Pedley Email: send email Telefono: -13754 Fax: -11111	UK (LONDON)	participant	0.00
9	VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG  Organization address address: De Boelelaan 1105 city: AMSTERDAM postcode: 1081 HV contact info Titolo: Dr. Nome: D. Cognome: Bonink Email: send email Telefono: +31 20 4444076 Fax: +31 20 4443688	NL (AMSTERDAM)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The selective delivery of bioactive agents (cytotoxics, radionuclides, cytokines) at the tumor site, while sparing normal tissues, represents one of the most promising avenues for the development of anticancer therapies with unprecedented efficacy and tolerability. Monoclonal antibodies represent the preferred vehicle for the targeted delivery of bioactive agents to cancer sites, as they can display a preferential accumulation in primary and metastatic tumor lesions already few hours after intravenous administration. Certain monoclonal antibody derivatives can remain on the neoplastic mass for several days, thus enabling the slow release of potent cytotoxics or the continuous action of bioactive agents such as cytokines or therapeutic radionuclides. The ADAMANT Project aims at the generation of anticancer agents of superior quality, which rely on the antibody-based delivery of cytotoxics, radionuclides or immunostimulatory cytokines to either vascular tumor antigens or to tumor cell membranes. While clinically-validated antibodies will allow the rapid development of therapeutic strategies based on novel antibody derivatives, innovative perfusion-based chemical proteomic technologies will facilitate the discovery of accessible and abundant tumor-associated antigens, ideally suited for the targeted delivery of bioactive agents to cancer sites. Imaging methodologies will guide us in the selection of antigens, antibodies and therapeutic agents with optimal pharmacokinetis and pharmacodynamics. Finally, therapy studies in tumor-bearing mice, featuring the use of antibody-derivatives in combination with other anti-cancer drugs (cytotoxic, biological, vascular disrupting agents) will provide insights about how to best translate the results of the ADAMANT Project to clinical development. The Project will be truly successful if at least one antibody-based tumor targeting agent enters full-blown industrial development programs by the end of the ADAMANT Project.'

Introduzione (Teaser)

European researchers used the selective binding ability of antibody molecules and cancer-specific antigens to deliver drugs directly to tumour sites. This approach boasts low toxicity and high specificity, raising anti-cancer immune responses through the targeted delivery of cytokines.